FDA approval pathway propels Sangamo Therapeutics shares upward: what’s next?
Sangamo Therapeutics experienced a significant surge in its stock price, jumping by as much as 53%, after the U.S. Food and Drug Administration (FDA) indicated ... Read More
InhaleRx secures A$38.5m deal to accelerate pain and mental health breakthroughs
Melbourne-based healthcare innovator InhaleRx Limited (ASX: IRX) has secured a substantial funding deal worth up to AUD 38.5 million, aiming to revolutionize the treatment of ... Read More
FDA approves Pfizer’s HYMPAVZI for breakthrough hemophilia treatment
In a major leap for hemophilia patients, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has granted approval for HYMPAVZI ... Read More
Echo IQ’s EchoSolv AS gains FDA approval—AI-powered solution to tackle underdiagnosed Aortic Stenosis
Sydney-based AI medical technology company, Echo IQ Limited, has achieved a significant breakthrough with the US Food and Drug Administration (FDA) clearance for its EchoSolv ... Read More
Breakthrough data from Vatiquinone trials propels PTC Therapeutics stock to 52-week high
PTC Therapeutics Inc. (NASDAQ: PTCT) is experiencing significant momentum within the biotechnology sector following a surge in its stock price to a 52-week high of ... Read More
Neuren Pharmaceuticals advances NNZ-2591 for Phelan-McDermid syndrome to Phase 3 clinical trial
Neuren Pharmaceuticals has secured approval from the United States Food and Drug Administration (FDA) to progress into the first-ever pivotal Phase 3 clinical trial of ... Read More
Immutep completes patient enrolment for Phase II trial of eftilagimod alpha in metastatic breast cancer
Immutep Limited, a clinical-stage biotechnology company specializing in advanced LAG-3 immunotherapies, has announced the completion of patient enrolment for its Phase II AIPAC-003 clinical trial. ... Read More
Summit Therapeutics set to begin HARMONi trial of Ivonescimab in EGFR-mutant lung cancer
Summit Therapeutics Inc. has announced a significant milestone in its oncology development efforts, completing patient enrollment for the HARMONi Phase III clinical trial. This pivotal ... Read More
FDA approves Bristol Myers Squibb’s Opdivo for expanded lung cancer treatment, boosting stock and investor sentiment
In a significant step forward for lung cancer treatment, the US Food and Drug Administration (FDA) has expanded its approval of Bristol Myers Squibb's Opdivo ... Read More
Eton Pharmaceuticals shocks investors with major acquisition: Shares explode to 52-week high
Eton Pharmaceuticals has sent shockwaves through the pharmaceutical industry after its shares soared to a 52-week high, fueled by the acquisition of the critical rare ... Read More